Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ABP vs NOVTU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABP Wins Head-to-Head Institutional Verdict (2–0 across 6 Pillars · 6–2 Matrix Metrics)

ABP Overall Winner 6-Pillar Tally: ABP 2 – 0 NOVTU (4 Tie) Matrix Metrics: ABP 6 – 2 NOVTU

As of Nov 16, 2026, Abpro Holdings, Inc (ABP) is the stronger overall head-to-head candidate over NOVTU (NOVTU) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). ABP carries a Unified Composite Score of 44.4/100 (HOLD) at $0.52 (N/M Forward P/E, 0.0% operating margin), whereas NOVTU carries 42.5/100 (HOLD) at $50.76 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: ABP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.2); meanwhile NOVTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABP vs NOVTU
ABP NASDAQ Head-to-Head Winner
Abpro Holdings, Inc Common Stock
Biological Products, (No Disgnostic Substances)
$0.52
-34.76% 1D
Market Cap $2.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.33β · 258% Vol
Unified Composite Score
44.4 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -36.3%), weak momentum, RSI 22
RSI-14: 22.2 · SMA20: $1.51 · SMA50: $3.29
NOVTU US Equity
NOVTU
Institutional Equity
$50.76
-1.05% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.70β · 65% Vol
Unified Composite Score
42.5 / 100 HOLD
Tech 30.0 Fund 45.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.0%), weak momentum, RSI 33
RSI-14: 33.1 · SMA20: $58.29 · SMA50: $59.48

6-Pillar Scorecard Institutional Category Breakdown (ABP 2 – 0 NOVTU)

Columns: Metric · ABP · NOVTU
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ABP
Revenue Growth (YoY) -100.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A N/A
Market Cap $2.2M N/A
3. Profitability & Quality ABP
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) 0.0% N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage 0.0% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABP (6) vs NOVTU (2)
Institutional Metric ABP NOVTU Criterion Row Edge
Market Capitalization
Scale
$2.2M N/A Larger Scale ABP
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% N/A Higher Growth ABP
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin ABP
Net Profit Margin
Profitability
0.0% N/A Higher Margin ABP
Return on Equity (ROE)
Capital Efficiency
0.0% N/A Higher ROE ABP
52-Week Range Position
Momentum
0% ($1–$32) 11% ($48–$77) Stronger Trend NOVTU
Beta / 30D Volatility
Risk Regime
2.33β · 258% Vol 1.70β · 65% Vol Lower Realized Risk NOVTU
Unified Institutional Score
Composite Signal
44.4 / 100 (HOLD) 42.5 / 100 (HOLD) Higher Composite ABP
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (0.0% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NOVTU +91.39 pp
ABP: -83.11% · NOVTU: +8.28%
3M Horizon NOVTU +112.61 pp
ABP: -91.34% · NOVTU: +21.27%
6M Horizon NOVTU +112.61 pp
ABP: -91.34% · NOVTU: +21.27%
1Y Horizon NOVTU +112.61 pp
ABP: -91.34% · NOVTU: +21.27%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABP vs NOVTU. Trailing 12-month operating profitability (ABP 0.0% vs NOVTU N/A) and valuation multiples (ABP N/M vs NOVTU N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E0.0% · N/M
NOVTU ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NOVTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NOVTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NOVTU Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABP vs NOVTU Key Questions & Quantitative Answers

As of Nov 16, 2026, Abpro Holdings, Inc (ABP) is the stronger overall head-to-head candidate over NOVTU (NOVTU) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). ABP carries a Unified Composite Score of 44.4/100 (HOLD) at $0.52 (N/M Forward P/E, 0.0% operating margin), whereas NOVTU carries 42.5/100 (HOLD) at $50.76 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: ABP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.2); meanwhile NOVTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABP leads the Growth & Scale pillar: ABP posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NOVTU at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ABP generates N/A in USD-normalized revenue versus N/A for NOVTU. In operating R&D and SG&A reinvestment, ABP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NOVTU.

ABP and NOVTU trade at balanced relative valuation multiples. ABP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NOVTU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABP (0.0% ROE) versus NOVTU (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ABP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.33β · 258% Vol realized risk). By comparison, NOVTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.70β · 65% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.